Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 401–500 of 1,029
Aerssens, J., Raeymaekers, P., Lilienfeld, S., Geerts, H., Konings, F., & Parys, W. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051238 · Cited by 98
Lipoproteins in the Central Nervous System: From Biology to Pathobiology
Raulin, A.-C., Martens, Y. A., & Bu, G. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104801 · Cited by 89
Prasher, V. P., Sajith, S. G., Rees, S. D., Patel, A., Tewari, S., Schupf, N., & Zigman, W. B. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2039 · Cited by 89
“A number of studies in the general population have found an association of the e2 allele with reduced risk for DAD (Corder et al., 1994) whilst others have not supported this finding (van Duijn et al., 1995).”
InfluentialApolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3
Rebeck, G. W., Kindy, M., & LaDu, M. J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4304 · Cited by 89
“This genetic correlation has been confirmed in a variety of populations and by a number of statistical approaches [16,30,47,80,102,142,145,156],and expanded to implicate apoE2 as a protective isoform in the development of AD [22,116].”
Monsell, S. E., Kukull, W. A., Roher, A. E., Maarouf, C. L., Serrano, G., Beach, T. G., Caselli, R. J., Montine, T. J., & Reiman, E. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1721 · Cited by 82
Differences between early and late onset Alzheimer's disease.
Panegyres, P. K., & Chen, H.-Y. (2013) · Europe PMC (PubMed Central) · Cited by 123
Apolipoprotein E Genotype and Cognitive Dysfunction after Noncardiac Surgery
Abildstrøm, H., Christiansen, M., Siersma, V., & Rasmussen, L. S. (2004) · Anesthesiology · doi:10.1097/00000542-200410000-00009 · Cited by 86
“A protective effect of the 2 allele on cognitive function has been demonstrated.(23) To take this possible interference into account, analysis of the influence of the APOE genotype on POCD was done in two ways.”
MethodStep by step: towards a better understanding of the genetic architecture of Alzheimer’s disease
Lambert, J.-C., Ramirez, A., Grenier-Boley, B., & Bellenguez, C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02076-1 · Cited by 87
“A year later, it was reported that the APOE ε 2 allele was associated with a two-fold decrease in that risk [9] – con fi rming the major role of the APOE gene in AD.”
BackgroundMulder, S. D., Nielsen, H. M., Blankenstein, M. A., Eikelenboom, P., & Veerhuis, R. (2014) · Glia · doi:10.1002/glia.22619 · Cited by 87
“On the contrary, people with ApoE-e2 allele are less likely to develop AD (Corder et al., 1994), have slower rates of cognitive decline (Wilson et al.”
BackgroundPotter, H., Wefes, I. M., & Nilsson, L. N. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00308-6 · Cited by 90
“Finally, apoE2, which shows protective activity against Alzheimer’ s disease in epidemiological studies [ 12 ], also suppressed the ability of apoE4 to promote A polymerization in vitro ([41]; Fig. 1). These results together with the finding that apoE4 individuals with Alzheimer’ s disease evidence greater amyloid loa…”
ResultKurz, A., Egensperger, R., Haupt, M., Lautenschlager, N., Romero, B., Graeber, M. B., & Muller, U. (1996) · Neurology · doi:10.1212/wnl.47.2.440 · Cited by 87
Apolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain
Roses, A. D. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0161 · Cited by 87
Self-citationJackson, R. J., Keiser, M. S., Meltzer, J. C., Fykstra, D. P., Dierksmeier, S. E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.024 · Cited by 86
Why lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Mui, S., William Rebeck, G., McKenna‐Yasek, D., Hyman, B. T., & Brown, R. H. (1995) · Annals of Neurology · doi:10.1002/ana.410380318 · Cited by 86
White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease
Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008864 · Cited by 84
“Analyses that included APOE e4 carrier status excluded 6 individuals with the e2/e4 genotype because these alleles have contrasting effects on dementia risk.(22,23)”
BackgroundThe role of APOE polymorphisms in late-onset dementias
Corder, E. H., Lannfelt, L., Bogdanović, N., Fratiglioni, L., & Mori, H. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050223 · Cited by 91
Self-citationGenetic factors in Alzheimer's disease: A review of recent advances
Levy‐Lahad, E., & Bird, T. D. (1996) · Annals of Neurology · doi:10.1002/ana.410400604 · Cited by 96
Cognitive Impairment and Dementia in Elderly People Living in Rural Benin, West Africa
Guerchet, M., Houinato, D., Paraiso, M. N., von Ahsen, N., Nubukpo, P., Otto, M., Clément, J.-P., Preux, P.-M., & Dartigues, J.-F. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000188661 · Cited by 84
“This frequency was significantly lower in persons with cognitive impairment and with dementia than in those with no cognitive impairment. Moreover, the absence of the APOE e2 allele is significantly associated with cognitive impairment. The protective role of e2 has already been suggested [”
BackgroundLandry, G. J., & Liu-Ambrose, T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00325 · Cited by 84
“These moderators are thought to include: protective genotypes (e.g., APOE-ε2 (Corder et al., 1994; Tanzi and Bertram, 2005)), good sleep quality (Lim et al., 2013), cardiovascular health, education, and other hallmarks of a healthy lifestyle such as life-long learning, exercise and eating well…”
BackgroundInfluentialChu, A. Y., Parekh, R. S., Astor, B. C., Coresh, J., Berthier‐Schaad, Y., Smith, M. W., Shuldiner, A. R., & Kao, W. H. L. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-108 · Cited by 86
“On the other hand, e2, the rarest ApoE isoform [28,32] has been shown to be associated with increased risk of CKD and lower GFR although it affords protection against Alzheimer's disease [33,34] and lowers cholesterol levels [35].”
BackgroundChao, L. L., DeCarli, C., Kriger, S., Truran, D., Zhang, Y., Laxamana, J., Villeneuve, S., Jagust, W. J., Sanossian, N., Mack, W. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065175 · Cited by 83
“Because the 2/4 combined allele is associated with a lower risk of AD [30], DTI Effects of WMH and Ab”
BackgroundOlfactory function in apoE knockout mice
Nathan, B. P., Yost, J., Litherland, M. T., Struble, R. G., & Switzer, P. V. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00219-5 · Cited by 85
“Furthermore, AD patients with theε4 allele usually showed an earlier age of onset and a more rapid progression of the disease [6,7,41].”
BackgroundSahota, A., Yang, M., Gao, S., Hui, S. L., Baiyewu, O., Gureje, O., Oluwole, S., Ogunniyi, A., Hall, K. S., & Hendrie, H. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420418 · Cited by 83
Apolipoprotein E, Synaptic Plasticity and Alzheimer's Disease
Poirier, J., Minnich, A., & Davignon, J. (1995) · Annals of Medicine · doi:10.3109/07853899509019253 · Cited by 83
ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-β1–42
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Blaine Stine, W., Manelli, A., Sullivan, P., Pasternak, J. F., & LaDu, M. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.011 · Cited by 82
“increase and decrease sporadic AD risk with 65% of AD attributable to the presence of q4 and an additional 23% attributable to the absence of an q2 (Corder et al., 1994).”
InfluentialJohnstone, D., Milward, E. A., Berretta, R., Moscato, P., & Initiative, F. T. A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 82
Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 82
The Complex Role of Apolipoprotein E in Alzheimer’s Disease: an Overview and Update
Mahoney‐Sanchez, L., Belaidi, A. A., Bush, A. I., & Ayton, S. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0839-z · Cited by 92
Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice
Maezawa, I., Maeda, N., Montine, T. J., & Montine, K. S. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-10 · Cited by 81
“At least for AD, inheritance of APOE2 is associated with apparent neuroprotection, perhaps related to delayed onset of illness by many years [11].”
BackgroundA cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics
Harwood, D. G., Barker, W. W., Loewenstein, D. A., Ownby, R. L., St. George-Hyslop, P., Mullan, M., & Duara, R. (1999) · Neurology · doi:10.1212/wnl.52.3.551 · Cited by 81
Chew, S. T. H., Newman, M. F., White, W. D., Conlon, P. J., Saunders, A. M., Strittmatter, W. J., Landolfo, K. P., Grocott, H. P., & Stafford‐Smith, M. (2000) · Anesthesiology · doi:10.1097/00000542-200008000-00008 · Cited by 96
Self-citationThe state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease
Rottkamp, C. A., Atwood, C., Joseph, J. A., Nunomura, A., Perry, G. L., & Smith, M. A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00069-4 · Cited by 87
“Interestingly, ApoE2 is capable of inhibiting the formation of fibrils and is protective against the development of AD [27].”
BackgroundAPOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80
Gylys, K. H., Fein, J. A., Tan, A. M., & Cole, G. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01643.x · Cited by 70
DLB and PDD: a role for mutations in dementia and Parkinson disease genes?
Meeus, B., Verstraeten, A., Crosiers, D., Engelborghs, S., den Broeck, M. V., Mattheijssens, M., Peeters, K., Corsmit, E., Elinck, E., Pickut, B. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.014 · Cited by 85
Lipid Metabolism and Glial Lipoproteins in the Central Nervous System
Hayashi, H. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.453 · Cited by 80
Ginns, E. I., Jean, P. S., Philibert, R. A., Galdzicka, M. M., Damschroder-Williams, P. J., Thiel, B., Long, R. T. L., Ingraham, L. J., Dalwaldi, H., Murray, M. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15531 · Cited by 80
Apolipoprotein E genotype and Lewy body disease
Lippa, C. F., Smith, T. W., Saunders, A. M., Crook, R., Pulaski-Salo, D., Davies, P., Hardy, J., Roses, A. D., & Dickson, D. W. (1995) · Neurology · doi:10.1212/wnl.45.1.97 · Cited by 84
Self-citationMulti-ethnic genome-wide association study identifies novel locus for type 2 diabetes susceptibility
Cook, J. P., & Morris, A. P. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.17 · Cited by 79
“Compared with the common APOE ε 3 allele, ε 4 increases the risk of LOAD and lowers the age at onset (AAO) of AD in a dose-dependent fashion, whilst the ε 2 allele confers a protective effect 23,24 .”
Apolipoprotein E 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
Berge, G., Sando, S. B., Rongve, A., Aarsland, D., & White, L. R. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307228 · Cited by 78
APOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation
Wijsman, E. M., Daw, E. W., Yu, X., Steinbart, E. J., Nochlin, D., Bird, T. D., & Schellenberg, G. D. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30087 · Cited by 79
“…et al., 2003]: the e4 allele is associated with reduced ageat-onset in a dose-dependent manner [Corder et al., 1993, 1998; Daw et al., 2000], and the e2 allele is associated with increased age-at-onset [Corder et al., 1994, 1998; Farrer et al., 1997; Daw et al., 2000], relative to the e3 allele.”
BackgroundNacmias, B., Latorraca, S., Piersanti, P., Forleo, P., Piacentini, S., Bracco, L., Amaducci, L. A., & Sorbi, S. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(94)11100-w · Cited by 81
TOMM40 ′523 variant and cognitive decline in older persons with APOE ε3/3 genotype
Yu, L., Lutz, M. W., Wilson, R. S., Burns, D. K., Roses, A. D., Saunders, A. M., Gaiteri, C., De Jager, P. L., Barnes, L. L., & Bennett, D. A. (2017) · Neurology · doi:10.1212/wnl.0000000000003614 · Cited by 78
Self-citationROSES, A. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32598.x · Cited by 78
Self-citationApolipoprotein E and ALzheimer's Disease: The Tip of the Susceptibility Iceberg
ROSES, A. D. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10653.x · Cited by 78
Self-citationDementia, quantitative neuroimaging, and apolipoprotein E genotype.
Bigler, E. D., Lowry, C. M., Anderson, C. V., Johnson, S. C., Terry, J., & Steed, M. (2000) · PubMed Central · Cited by 85
Liao, F., Zhang, T. J., Jiang, H., Lefton, K. B., Robinson, G. O., Vassar, R., Sullivan, P. M., & Holtzman, D. M. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0250-y · Cited by 77
“The strongest known genetic risk factor for late onset AD is the ε4 allele of apolipoprotein E (apoE), while the ε2 allele is protective [7, 8, 33].”
Cognitive reserve and cortical thickness in preclinical Alzheimer’s disease
Pettigrew, C. A., Soldan, A., Zhu, Y., Wang, M., Brown, T., Miller, M. I., & Albert, M. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9581-y · Cited by 97
Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases
Mathews, P. M., & Levy, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01347 · Cited by 75
Presence of ApoE ε4 Allele Associated with Thinner Frontal Cortex in Middle Age
Fennema-Notestine, C., Panizzon, M. S., Thompson, W. R., Chen, C.-H., Eyler, L. T., Fischl, B., Franz, C. E., Grant, M. D., Jak, A. J., Jernigan, T. L., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0002 · Cited by 76
“In addition, ε2 carriers may evidence a reduced rate of cognitive decline [8, 15, 19–21] and fewer are diagnosed with AD [8].”
BackgroundGenetic Markers of Alzheimer’s Disease
Perković, M. N., & Pivac, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9721-0_3 · Cited by 90
Single cell gene expression profiling in Alzheimer’s disease
Ginsberg, S. D., Che, S., Counts, S., & Mufson, E. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.007 · Cited by 79
“In contrast, the presence of the APOE 2 allele may decrease the risk for AD but is associated with a higher risk of hemorrhage due to cerebral amyloid angiopathy.(95)”
BackgroundXu, P.-T., Li, Y.-J., Qin, X.-J., Scherzer, C. R., Xu, H., Schmechel, D. E., Hulette, C. M., Ervin, J., Gullans, S. R., Haines, J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.07.004 · Cited by 76
“The APOE4 allele increases the risk and lowers the age of onset of AD in a dosedependent manner (Corder et al., 1994).”
BackgroundSelf-citationCholesterol-related genes in Alzheimer's disease
Wollmer, M. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.009 · Cited by 95
Apolipoprotein E and Neuromuscular Disease: A Critical Review of the Literature
Bedlack, R. S., Strittmatter, W. J., & Morgenlander, J. C. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1561 · Cited by 76
“In contrast, each APOE2 allele decreases AD risk and increases the age of onset.(15) Functional outcome after intracerebral hemorrhage is worse in patients with an APOE4 allele compared with those without one.”
BackgroundSelf-citationApolipoprotein E Genotype and Outcome in Aneurysmal Subarachnoid Hemorrhage
Leung, C. H. S., Poon, W. S., Yu, L., Wong, G. K. C., & Ng, H. (2002) · Stroke · doi:10.1161/hs0202.102326 · Cited by 76
Jarvik, G. P., Larson, E. B., Goddard, K. A. B., Schellenberg, G. D., & Wijsman, E. M. (1996) · PubMed Central · Cited by 85
Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation
Saroja, S. R., Gorbachev, K., Julia, T., Goate, A. M., & Pereira, A. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108870119 · Cited by 75
Nochlin, D., Bird, T. D., Nemens, E. J., Ball, M. J., & Sumi, S. M. (1998) · Annals of Neurology · doi:10.1002/ana.410430124 · Cited by 75
Locke, P. A., Conneally, P. M., Tanzi, R. E., Gusella, J. F., & Haines, J. L. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120108 · Cited by 75
Self-citationInsulin resistance, neuroinflammation, and Alzheimer’s disease
Najem, D., Bamji-Mirza, M., Chang, N., Liu, Q. Y., & Zhang, W. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0050 · Cited by 74
Jokar, S., Khazaei, S., Behnammanesh, H., Shamloo, A., Erfani, M., Beiki, D., & Bavi, O. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00606-2 · Cited by 79
D2 dopamine receptor and GABAA receptor β3 subunit genes and alcoholism
Noble, E. P., Zhang, X., Ritchie, T. L., Lawford, B. R., Grosser, S. C., Young, R. M., & Sparkes, R. S. (1998) · Psychiatry Research · doi:10.1016/s0165-1781(98)00084-5 · Cited by 87
Molecular Genetics of Neurodegenerative Dementias
Hinz, F. I., & Geschwind, D. H. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a023705 · Cited by 73
“Interestingly, the APOE12 allele appears to be protective and has been shown to decrease the risk of AD as well as to increase longevity (Corder et al. 1994).”
BackgroundApolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells
Sacre, S. M., Stannard, A. K., & Owen, J. S. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00261-8 · Cited by 73
Genetic risk factors in Alzheimer's disease.
Tilley, L. A., Morgan, K., & Kalsheker, N. A. (1998) · Molecular Pathology · doi:10.1136/mp.51.6.293 · Cited by 88
Aβ42 neurotoxicity in primary co-cultures: effect of apoE isoform and Aβ conformation
Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., & LaDu, M. J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.05.024 · Cited by 72
“ApoE2, on the other hand, offers cognitive protection from aging, as well as AD [7,67].”
BackgroundChoi, K., Lee, J., Gunasekaran, T., Kang, S., Lee, W., Jeong, J., Lim, H., Zhang, X., Zhu, C., Won, S.-Y., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081236 · Cited by 72
“The less common ε2 allele is protective against AD [10,11].”
BackgroundSelf-citationLewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Apolipoprotein‐E Genotyping of Diabetic Dementia Patients: Is Diabetes Rare in Alzheimer's Disease?
Nielson, K. A., Nolan, J. H., Berchtold, N. C., Sandman, C. A., Mulnard, R. A., & Cotman, C. W. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01857.x · Cited by 72
ApoE, Alzheimer's Disease, and Recovery from Brain Stressa
ROSES, A. D., & SAUNDERS, A. M. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48471.x · Cited by 73
Self-citationAssociation of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Garo-Pascual, M., Gaser, C., Zhang, L., Tohka, J., Medina, M., & Strange, B. A. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00079-x · Cited by 83
A Brief History of Alzheimer's Disease Gene Discovery
Tanzi, R. E. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129044 · Cited by 71
“One copy of the 4-allele of APOE increases AD risk by ∼4-fold and two copies, greater than ten-fold; the 2-allele of APOE is protective for AD [33].”
Lyall, D. M., Harris, S. E., Bastin, M. E., Muñoz Maniega, S., Murray, C., Lutz, M. W., Saunders, A. M., Roses, A. D., Valdés Hernández, M. D. C., Royle, N. A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.006 · Cited by 71
“APOE plays a role in the transport and metabolism of lipids in the human body and brain (Bu et al., 2009; Corder et al., 1994).”
BackgroundInfluentialSelf-citationCouttas, T. A., Kain, N., Tran, C., Chatterton, Z., Kwok, J. B., & Don, A. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171054 · Cited by 79
Apolipoprotein E type ϵ4 allele frequency is increased in patients with schizophrenia
Harringtonaa, C. R., Roth, M., Xuereb, J. H., McKenna, P. J., & Wischik, C. M. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12218-4 · Cited by 78
Ionizing radiation and genetic risks
Sankaranarayanan, K., & Chakraborty, R. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00106-8 · Cited by 74
New Insights into the Genetics of Alzheimer's Disease
Hardy, J. (1996) · Annals of Medicine · doi:10.3109/07853899609033127 · Cited by 71
Latimer, C. S., Keene, C. D., Flanagan, M. E., Hemmy, L. S., Lim, K. O., White, L. R., Montine, K. S., & Montine, T. J. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx030 · Cited by 70
Sex‐specific transcriptome of spinal microglia in neuropathic pain due to peripheral nerve injury
Fiore, N. T., Yin, Z., Güneykaya, D., Gauthier, C. D., Hayes, J. P., D’Hary, A., Butovsky, O., & Moalem‐Taylor, G. (2022) · Glia · doi:10.1002/glia.24133 · Cited by 76
Lu, P. H., Thompson, P. M., Leow, A., Lee, G. J., Lee, A., Yanovsky, I., Parikshak, N., Khoo, T., Wu, S., Geschwind, D., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101398 · Cited by 70
“While these results may be suggestive of a protective role of the 2 genotype against the development of AD [2, 5, 9, 10], this cannot be conclusively demonstrated without the inclusion of an 3 3 group, since it is possible that individuals with the 3 3 genotype may show the same attenuated atrophy rate as the 2 group…”
BackgroundEpigenetic signature and enhancer activity of the human APOE gene
Yu, C.-E., Cudaback, E., Foraker, J., Thomson, Z., Leong, L., Lutz, F., Gill, J. A., Saxton, A., Kraemer, B., Navas, P., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt354 · Cited by 70
Relkin, N. R., Kwon, Y. J., Tsai, J., & Gandy, S. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32608.x · Cited by 75
Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., & Brinkmalm, G. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.033 · Cited by 69
Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies
Singleton, A. B., Wharton, A., O’Brien, K. K., Walker, M. P., McKeith, I. G., Ballard, C. G., O’Brien, J., Perry, R. H., Ince, P. G., Edwardson, J. A., et al. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066022 · Cited by 69
Marioni, R. E., Campbell, A., Scotland, G., Hayward, C., Porteous, D. J., & Deary, I. J. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.210 · Cited by 68
Association of Apolipoprotein E Polymorphisms With Normal Tension Glaucoma in a Chinese Population
Lam, C. Y., Fan, B. J., Wang, D. Y., Tam, P. O. S., Yung Tham, C. C., Leung, D. Y. L., Ping Fan, D. S., Chiu Lam, D. S., & Pang, C. P. (2006) · Journal of Glaucoma · doi:10.1097/01.ijg.0000212217.19804.a7 · Cited by 68
Effect of the Apolipoprotein E ε4 Allele on White Matter Hyperintensities in Dementia
Hirono, N., Yasuda, M., Tanimukai, S., Kitagaki, H., & Mori, E. (2000) · Stroke · doi:10.1161/01.str.31.6.1263 · Cited by 73
Paternal age is a risk factor for Alzheimer disease in the absence of a major gene
Bertram, L., Busch, R., Spiegl, M., Lautenschlager, N. T., Müller, U., & Kurz, A. (1998) · Neurogenetics · doi:10.1007/s100480050041 · Cited by 74
“Demographic and clinical variables as well as ApoE e4 allele frequencies in the AD subgroups were in good agreement with those found in other Caucasian AD populations [4, 5, 32 , 33] (Table 1). Fathers of low MGAD patients were significantly older at birth of their children than fathers of high MGAD patients (35.7B8.1…”
ResultDukart, J., Sambataro, F., Bertolino, A., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150570 · Cited by 68
“1 [55–92] 74.”
Apolipoprotein E allele distribution in parents of Down's syndrome children
Avramopoulos, D., Grigoriadou, M., Petersen, M. B., Mikkelsen, M., Petersen, M. B., & Vassilopoulos, D. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91346-x · Cited by 78
Payami, H., Grimslid, H., Oken, B., Camicioli, R. M., Sexton, G. J., Dame, A., Howieson, D. B., & Kaye, J. A. (1997) · PubMed Central · Cited by 71
Welsh‐Bohmer, K. A., Gearing, M., Saunders, A. M., Roses, A. D., & Mirra, S. (1997) · Annals of Neurology · doi:10.1002/ana.410420308 · Cited by 67
Self-citationTesi, N., van der Lee, S. J., Hulsman, M., Jansen, I. E., Stringa, N., van Schoor, N. M., Scheltens, P., van der Flier, W. M., Huisman, M., Reinders, M. J. T., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01018-7 · Cited by 67
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels
Steward, A., Biel, D., Dewenter, A., Roemer, S., Wagner, F., Dehsarvi, A., Rathore, S., Otero Svaldi, D., Higgins, I., Brendel, M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.4038 · Cited by 67
Macrophage-Mediated Degradation of β-Amyloid via an Apolipoprotein E Isoform-Dependent Mechanism
Zhao, L., Lin, S., Bales, K. R., Gelfanova, V., Koger, D., DeLong, C., Hale, J., Liu, F., Hunter, J. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5302-08.2009 · Cited by 67
“In contrast, inheritance of the 2 allele appears to be protective (Corder et al., 1994).”
BackgroundKlein, R. C., Mace, B. E., Moore, S. D., & Sullivan, P. M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.027 · Cited by 67
“In contrast, APOE2 carriers represent approximately 15% of the population and theoretically deter Alzheimer’s disease compared to presence of the APOE3 allele (Corder et al., 1994).”
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.